Epidemiology of fibrolamellar hepatocellular carcinoma in the USA, 2000-10
- PMID: 23708586
- PMCID: PMC4145809
- DOI: 10.1136/gutjnl-2013-305164
Epidemiology of fibrolamellar hepatocellular carcinoma in the USA, 2000-10
Keywords: Hepatocellular CARCINOMA.
Conflict of interest statement
The authors report no potential conflicts of interest.
Figures
Comment on
-
Prospective validation of an immunohistochemical panel (glypican 3, heat shock protein 70 and glutamine synthetase) in liver biopsies for diagnosis of very early hepatocellular carcinoma.Gut. 2012 Oct;61(10):1481-7. doi: 10.1136/gutjnl-2011-301862. Epub 2012 Jan 27. Gut. 2012. PMID: 22287594
References
-
- Tremosini S, Forner A, Boix L, et al. Prospective validation of an immunohistochemical panel (glypican 3, heat shock protein 70 and glutamine synthetase) in liver biopsies for diagnosis of very early hepatocellular carcinoma. Gut. 2012;61:1481–7. - PubMed
-
- Fritz A, Percy C, Jack A, et al., editors. International Classification of Diseases for Oncology. 3. Geneva: World Health Organzation; 2010.
-
- El-Serag HB, Davila JA. Is fibrolamellar carcinoma different from hepatocellular carcinoma? A US population-based study. Hepatology. 2004;39:798–803. - PubMed
-
- Okuda K. Natural history of hepatocellular carcinoma including fibrolamellar and hepato-cholangiocarcinoma variants. J Gastroenterol Hepatol. 2002;17:401–5. - PubMed
-
- Craig JR, Peters RL, Edmondson HA, et al. Fibrolamellar carcinoma of the liver: a tumor of adolescents and young adults with distinctive clinico-pathologic features. Cancer. 1980;46:372–9. - PubMed
Publication types
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical